83/100BAbbott Laboratories stock forecast 2026–2030
Analysts' average 12-month price target for Abbott Laboratories is 121.36, 5.0% above the current price of 115.55. Their targets range from 112.00 to 130.00.
Of the 21 firms that rated Abbott Laboratories in the past 12 months, 20 rate it buy or strong buy, 1 hold and 0 sell or strong sell (each firm at its latest rating); on average they come to Buy.
Analysts' 1-year price targets range from 112.00 to 130.00, with an average of 121.36.
| Strong buy | 0 | |
| Buy | 20 | |
| Hold | 1 | |
| Sell | 0 | |
| Strong sell | 0 |
12-month price target
| Highest target | 130.00 |
| Average target | 121.36 |
| Lowest target | 112.00 |
| Current price | 115.55 |
Abbott Laboratories price target history
Have analysts recently raised or lowered their Abbott Laboratories price target and rating?
How analysts rate Abbott Laboratories, month by month
20 of 21 firms rate it buy now, against 14 of 16 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Abbott Laboratories analyst upgrades, downgrades and price targets
The latest rating change came on 27 October 2026, when Argus Research downgraded Abbott Laboratories from Buy to Hold. The most recent new target came from UBS on 23 October 2026: 120.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 27 Oct 2026 | Argus Research | Downgraded · Buy → Hold | — | — | — |
| 23 Oct 2026 | UBS | — | 125.00 → 120.00 | -4.0% | 103.08 |
| 23 Oct 2026 | Wells Fargo | Reiterated · Overweight | 119.00 → 120.00 | +0.8% | 102.51 |
| 22 Oct 2026 | BTIG Marie Thibault | Reiterated · Buy | 134.00 → 125.00 | -6.7% | 100.57 |
| 22 Oct 2026 | Wells Fargo | Reiterated · Overweight | 122.00 → 119.00 | -2.5% | 100.57 |
| 22 Oct 2026 | Robert W. Baird | — | 121.00 → 123.00 | +1.7% | 100.57 |
| 16 Oct 2026 | New Street | — | 145.00 → 120.00 | -17.2% | 104.60 |
| 6 Oct 2026 | Barclays | — | 143.00 → 120.00 | -16.1% | 98.17 |
| 2 Oct 2026 | Redburn Partners Ed Ridley-Day | — | 127.00 | — | 96.71 |
| 2 Oct 2026 | Rothschild & Co | Upgraded · Neutral → Buy | — | — | — |
| 13 Aug 2026 | Wolfe Research | Upgraded · Peer Perform → Outperform | 130.00 | — | 110.92 |
| 28 Jul 2026 | UBS Patrick Wood | Reiterated · Buy | 115.00 → 125.00 | +8.7% | 108.84 |
| 20 Jul 2026 | Benchmark Co. | — | 120.00 | — | 100.67 |
| 17 Jul 2026 | Piper Sandler | Reiterated · Overweight | 115.00 → 118.00 | +2.6% | 98.82 |
| 16 Jul 2026 | BTIG | — | 145.00 → 134.00 | -7.6% | 98.82 |
| 6 Jul 2026 | Evercore ISI Vijay Kumar | Reiterated · Outperform | 138.00 → 112.00 | -18.8% | 93.64 |
| 30 Jun 2026 | Robert W. Baird David Rescott | — | 121.00 | — | 90.68 |
| 22 Apr 2026 | Daiwa | — | 92.00 | — | 92.75 |
| 20 Apr 2026 | Barclays Matt Miksic | Reiterated · Overweight | 142.00 → 143.00 | +0.7% | 96.83 |
| 17 Apr 2026 | UBS | — | 158.00 → 115.00 | -27.2% | 95.46 |
| 17 Apr 2026 | Piper Sandler | Reiterated · Overweight | 135.00 → 115.00 | -14.8% | 95.46 |
| 17 Apr 2026 | Stifel Nicolaus | Reiterated · Buy | 120.00 | — | 95.46 |
| 13 Mar 2026 | UBS Danielle Antalffy | — | 132.00 → 158.00 | +19.7% | 108.42 |
| 13 Mar 2026 | New Street | — | 145.00 | — | 108.14 |
| 2 Feb 2026 | Barclays | Reiterated · Overweight | 169.00 → 142.00 | -16.0% | 109.30 |
| 29 Jan 2026 | Loop Capital Markets Ilya Zubkov | — | 120.00 | — | 106.09 |
| 29 Jan 2026 | Freedom Broker | Upgraded · Hold → Buy | — | — | — |
| 23 Jan 2026 | Evercore ISI | Reiterated · Outperform | 144.00 → 138.00 | -4.2% | 108.61 |
| 23 Jan 2026 | UBS | — | 132.00 | — | 108.60 |
| 23 Jan 2026 | Mizuho Securities Anthony Petrone | — | 125.00 | — | 108.60 |
| 23 Jan 2026 | Piper Sandler | Reiterated · Overweight | 135.00 | — | 108.60 |
| 23 Jan 2026 | Bernstein | Reiterated · Outperform | 154.00 → 125.00 | -18.8% | 108.60 |
| 23 Jan 2026 | Wells Fargo Larry Biegelsen | Reiterated · Overweight | 146.00 → 122.00 | -16.4% | 108.60 |
| 9 Jan 2026 | Bernstein Lee Hambright | Reiterated · Outperform | 154.00 | — | 126.18 |
| 9 Jan 2026 | Goldman Sachs | — | 157.00 → 152.00 | -3.2% | 126.18 |
| 5 Jan 2026 | Evercore ISI | — | 144.00 | — | 123.97 |
| 5 Jan 2026 | Barclays | Reiterated · Overweight | 162.00 → 169.00 | +4.3% | 124.19 |
| 22 Dec 2025 | BTIG Marie Thibault | — | 145.00 | — | 126.24 |
| 21 Nov 2025 | Tigress Financial | — | 145.00 | — | 128.13 |
Abbott Laboratories EPS and revenue estimates
Analysts expect Abbott Laboratories's EPS to grow 20.5% a year until 2028. Over the last 5 years it grew 8.3% a year, and over the last 3 years it fell 1.6%.
Analysts expect Abbott Laboratories's revenue to grow 8.8% a year until 2028, faster than over the last 5 years (5.1% a year) and the last 3 years (0.5%).
Revenue
EPS
Does Abbott Laboratories beat earnings estimates?
On average, analysts' EPS estimate was 1.0% off the result, either way, and their revenue estimate 0.8%, over the last 12 quarters.
- EPS beats
- 75 / 136
- Revenue beats
- 75 / 120
- Average EPS surprise, last 12
- +1.0%
- Since
- January 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 21 Oct 2026 | 1.42 | 1.42 | 0.0% | 12.99B | 13.01B | +0.2% |
| Q2 FY2026 | 16 Jul 2026 | 1.28 | 1.31 | +2.3% | 12.52B | 12.59B | +0.6% |
| Q1 FY2026 | 16 Apr 2026 | 1.14 | 1.15 | +0.9% | 11.00B | 11.16B | +1.5% |
| Q4 FY2025 | 22 Jan 2026 | 1.50 | 1.50 | 0.0% | 11.80B | 11.46B | -2.9% |
| Q3 FY2025 | 15 Oct 2025 | 1.30 | 1.30 | 0.0% | 11.39B | 11.37B | -0.2% |
| Q2 FY2025 | 17 Jul 2025 | 1.26 | 1.26 | 0.0% | 11.09B | 11.14B | +0.5% |
| Q1 FY2025 | 16 Apr 2025 | 1.07 | 1.09 | +1.9% | 10.41B | 10.36B | -0.5% |
| Q4 FY2024 | 22 Jan 2025 | 1.34 | 1.34 | 0.0% | 11.03B | 10.97B | -0.5% |
| Q3 FY2024 | 16 Oct 2024 | 1.20 | 1.21 | +0.8% | 10.55B | 10.64B | +0.8% |
| Q2 FY2024 | 18 Jul 2024 | 1.10 | 1.14 | +3.6% | 10.37B | 10.38B | +0.1% |
| Q1 FY2024 | 17 Apr 2024 | 0.96 | 0.98 | +2.6% | 9.88B | 9.96B | +0.8% |
| Q4 FY2023 | 24 Jan 2024 | 1.19 | 1.19 | 0.0% | 10.18B | 10.24B | +0.6% |
Abbott Laboratories stock price 2026–2030: scenarios
If Abbott Laboratories's earnings keep growing at the 8.1% a year analysts expect to FY2028, it would earn about 7.59 a share in FY2030. At the P/E it has traded at over the last five years (14.7 to 35.5) that is 111.99 to 269.22 a share, or 220.11 at its average P/E of 29.0. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 5.52 | 81.36 | 159.91 | 195.59 |
| FY2027 | 5.93 | 87.52 | 172.00 | 210.39 |
| FY2028 | 6.50 | 95.88 | 188.44 | 230.48 |
| FY2029 (extrapolated) | 7.03 | 103.62 | 203.66 | 249.10 |
| FY2030 (extrapolated) | 7.59 | 111.99 | 220.11 | 269.22 |
Each year's EPS is the analysts' consensus to FY2028; the years after continue its 8.1% a year. Bear, base and bull apply the lowest, average and highest P/E of the last five fiscal year ends (14.7, 29.0, 35.5).
Is Abbott Laboratories stock undervalued or overvalued?
Abbott Laboratories's P/E of 42.8 is near the top of its 5-year range (13.2 to 42.8, median 29.7). It is within 5% of its 5-year high. Analysts expect faster growth than in recent years, which can explain part of the high P/E. Buyers pay less for each point of growth than usual: a PEG of 2.1 on expected growth against 3.6 on its median P/E and past five years' growth. Fair value is not a reliable guide for Abbott Laboratories: its earnings swing (EPS fell 51.3% in FY2025), so its usual P/E would mislead. Its forward P/E, on the consensus for FY2026, is 20.9.
- Price to earnings ratio (TTM)
- 42.80
- Five-year median P/E
- 29.72
- Five-year P/E range
- 13.2 – 42.8
- Forward P/E (FY2026)
- 20.94
- PEG ratio
- 5.30
- To the average target
- +5.0%
Most undervalued US stocks
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 66.390 | 128.2462Price 66.39185 | +93.2% | |
| 101.860 | 195.27146Price 101.86244 | +91.7% | |
| 123.790 | 235.44177Price 123.79294 | +90.2% | |
| 200.280 | 359.04269Price 200.28449 | +79.3% | |
| 227.150 | 406.28305Price 227.15508 | +78.9% | |
| 159.100 | 284.37213Price 159.10355 | +78.7% | |
| 105.320 | 175.76132Price 105.32220 | +66.9% |
Furthest below the fair value on each stock's page, updated every day.